In recent days, the spread of monkeypox virus has continued to attract attention. According to media reports, the number of countries reporting confirmed cases of monkeypox has increased to 15. How about the technical reserves of domestic testing reagents and other products Can the "monkeypox concept stocks" rising in recent days continue to boil? Recently, a number of listed companies responded intensively
A number of listed companies said they had technical reserves
While monkeypox virus is spreading in many countries, the "monkeypox concept stocks" on the A-share market have also been boiling for many days. In recent days, many A-share listed companies have responded to the technical reserves of nucleic acid detection reagents and other related products.
On the 22nd, the official wechat of Shengxiang biology announced that the company has reserved monkeypox virus nucleic acid detection kit (PCR fluorescent probe method) in its scientific research products, which can quickly identify monkeypox virus by specifically detecting the nucleic acid fragment of monkeypox virus.
On the same day, * ST Kehua said on the investor interaction platform that recently, many overseas countries have reported monkeypox cases one after another. Our company has organized R & D personnel for the first time to complete the technical reserve of monkeypox virus nucleic acid detection kit (PCR fluorescent probe method).
On the 23rd, Zhijiang biology said on the interactive platform that the product monkeypox virus nucleic acid determination kit (fluorescence PCR method) developed by the company has obtained the EU CE certification. There is a product introduction on the company's official website. At present, the kit has small batch orders at home and abroad.
There is uncertainty in market demand. Can "monkeypox concept stocks" continue to boil?
After the sharp rise on the 20th, Zhijiang biology achieved a 20% limit on the 23rd, and Shengxiang biology, West Point pharmaceutical, Baike biology and Haichen pharmaceutical all increased by more than 11%.
However, after the "monkeypox concept stocks" continued to boil for many days, some listed companies issued announcements of abnormal fluctuations in stock trading.
Zhijiang biology announced on the evening of the 23rd that the monkeypox virus nucleic acid determination kit (fluorescent PCR method) produced by the company is affected by market competition, product competitiveness and channel ability of the company, customer recognition and other factors, and the sales and profit contribution are uncertain. There is uncertainty about the impact of the overseas market revenue of the above products on the overall revenue of the company. Please invest rationally.
Screenshot from Zhijiang biological announcement
On the same day, Baike biology announced the abnormal fluctuation of stock trading, saying that the company's varicella vaccine could not prevent monkeypox, and the company currently had no products related to monkeypox virus prevention.
On the 24th, Daan gene announced that the company's monkeypox virus nucleic acid detection kit (fluorescence PCR method) obtained the CE registration certificate on the evening of May 23, 2022, Beijing time. The CE registration certificate of the above products has enriched the company's product portfolio, broadened the application field of the company's products, and responded to the needs of overseas markets in time.
However, investors are still in the development stage of the above-mentioned products. Please note that the market demand is still uncertain, and the above-mentioned products are also in the development stage.
In early trading on the 24th, poxvirus prevention and control concept stocks fell. As of the morning closing, Daan gene rose 2.47%, Zhijiang biology rose 2.76%, and the shares of Shengxiang biology, West Point pharmaceutical, * ST Kehua, Haichen pharmaceutical and Baike biology fell sharply, among which Baike biology fell by more than 11%.
Many countries require cases and close contact personnel to be isolated, and experts call for external defense input
Although the market demand space of monkeypox virus related detection reagent products is not clear, the spread of the virus has aroused the vigilance of health experts.
Recently, Zhu Huachen, an associate professor of the school of public health of the University of Hong Kong, stressed in an interview with the media that for the time being, there are no reports of monkeypox cases in China, so there is no need to panic, but don't take it lightly. We should do a good job in external prevention and input, and the supporting detection reagents should keep up.
In terms of vaccines, earlier who data showed that the effective rate of smallpox vaccine against monkeypox virus reached 85%.
At the same time, in foreign countries, some countries have asked for isolation of confirmed cases.
According to foreign media reports, the Belgian health authorities had earlier decided to require monkeypox cases to be isolated for 21 days, making it the first country in the world to require monkeypox cases to be isolated.
On May 23 local time, the British health and Safety Authority issued a statement that due to the 36 new cases of monkeypox in England and the first case of monkeypox in Scotland, the number of monkeypox cases in the UK has increased to 57. The statement said the epidemic was "serious and worrying", but the risk to the UK population remained low.
The new guidelines recently issued by the British health and safety agency suggest that personnel in close contact with confirmed cases of monkeypox should be isolated for 21 days.